Organon’s stock rose 8.4% to $7.49 in pre‑market trading after reports of Sun Pharma’s $12 billion binding bid.
Sun Pharmaceutical Industries has completed three months of due diligence and is finalising financing before submitting a firm offer in coming weeks.
Organon, a women’s health focused drugmaker, did not comment on the potential acquisition outside business hours.